News
NET Patient Research Study in New York City, May 3
Do you live in or near New York City – here’s a great opportunity to participate in a neuroendocrine tumor (NET) research study on Thursday, May 3 in Manhattan. You can make a difference for NET patients by sharing your opinions on a device in development …
READ MOREEndocrinology Society Recognizes Neuroendocrine Cancer Physician and Researcher for Excellence at 2018 Annual Meeting
Congratulations to Amit Tirosh, MD, neuroendocrine cancer physician and researcher, whose work was recognized for excellence at the Endocrinology Society’s 2018 Annual Meeting. Dr. Tirosh will soon be establishing and leading a new NET center at …
READ MOREPlease Help Pass a Bill That Could Result in Early Diagnosis for Neuroendocrine Cancer Patients — Deadline Extended to April 16
NET patients, friends and families – we need your help! Greta Stifel, founder of the Stifle Cancer Foundation, NET patient thriver, advocate and political activist, has created and submitted to the State of Connecticut Public Health Committee and…
READ MOREPlease Help Pass a Bill That Could Result in Earlier Diagnosis for Neuroendocrine Cancer Patients
NET patients, friends and families – we need your help! Greta Stifel, founder of the Stifle Cancer Foundation, NET patient thriver, advocate and political activist, has created and submitted to the State of Connecticut…
READ MOREClinical Nurse Educator Program Established for Neuroendocrine Tumor Patients on Xermelo
Are you a neuroendocrine tumor patient who is taking or has been prescribed Xermelo? Lexicon Pharmaceuticals is now offering a new Clinical Nurse Educator Program (CNE) available to you at no charge. Click here to read more…
READ MOREExciting News about Edward M. Wolin, MD, CCF’s Co-Medical Director
It is with great pleasure that the Carcinoid Cancer Foundation announces that Edward M. Wolin, MD, Co-Medical Director of CCF, has been named Director of the Center for Carcinoid and Neuroendocrine Tumors at The Mount Sinai Hospital in New York City, …
READ MOREFacebook Live with Neuroendocrine Cancer Expert Richard R.P. Warner, MD
In celebration of the Carcinoid Cancer Foundation’s 50th anniversary in March 2018, CCF presented a Facebook LIVE event with Richard R.P. Warner, MD, founder of CCF and one of the world’s leading neuroendocrine cancer experts, on February 2, 2018. …
READ MOREFDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). …
READ MORENew NET Fellowship Established at Stanford University School of Medicine
Stanford University School of Medicine in California has established a new one-year Neuroendocrine Tumor (NET) Fellowship under the direction of NET expert Pamela L. Kunz, MD, who is Director of the Stanford Neuroendocrine Tumor Program and a Board…
READ MOREArizona Symposium on Neuroendocrine Cancer — Join In-Person or Online
The Arizona Carcinoid & Neuroendocrine Foundation invites you to attend A Symposium on Neuroendocrine Cancer on Saturday, December 16, 2017. Attendance is available in-person at Banner MD Anderson Cancer Center in Gilbert, Arizona, or online. …
READ MORE